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Abstract: 
 
Background: Insulin treated patients with Type 2 Diabetes require specialist multidisciplinary 
input to achieve treatment targets. We compared the demographics; achievement of combined 
NICE targets for HbA1c (<7.5%), blood pressure (<140/80) and total cholesterol (<4mmol/L); 
and insulin use between patients from a local Integrated Diabetes Service with a representative 
UK population 
Methods: Cross-sectional evaluation of individual patient data from six randomly selected 
primary Care practices in Erewash Integrated Diabetes service was compared with The Health 
Improvement Network (THIN), UK primary care database. 
Results: Baseline age (61.5years vs 65.8 years; p <0.0001 and duration of insulin (4.3 vs 6.3 
years, P<0.0001) use was lower in the THIN population. Mean HbA1c was similar between 
the two cohorts but weight, blood pressure, total and LDL cholesterol was significant lower in 
the Erewash population compared with THIN.  The combined achievement of HbA1c, total 
cholesterol and blood pressure was 17.5% in the Erewash cohort compared with 9.6% in the 
UK THIN cohort (p<0.0001). There was a higher proportion of insulin users on basal-bolus 
than premix in the Erewash cohort (89.3% vs 10.7%) compared with THIN (59.0% vs 41.1%). 
Proportion of patients who received concurrent oral glucose lowering therapies in the Erewash 
integrated service was lower, except for SGLT2-inhibitor, (2.5% in the Erewash vs 0.5% in the 
THIN; p<0.0001).  
Conclusion: This model of integrated diabetes service appears to confer better clinical 
outcomes compared with the UK population. Further studies are required to investigate impact 
of this service model on health economic, patients’ pathway and patient experience.  
   
Introduction:  
In view of the significant vascular benefits of tight glucose control in patients with type 2 
diabetes (T2D) [1], consensus guidelines have recommended aggressive treatment escalations, 
including the earlier use of insulin therapy in patients with T2D in order to achieve optimal 
HbAlc target [2], an important Quality and Outcomes Framework (QOF) target for general 
practitioners [3]. The management of insulin treatment however is complex. Local preferences 
of healthcare providers and guidelines of Clinical Commissioning Groups (CCGs) plays an 
important role in determining patients’ care package which includes advice on lifestyle 
modification, compliance, choice of insulin therapies and regimens, as well as education on 
self-titration of insulin dose. 
 
Due to the rising cost and prevalence of diabetes [4], the responsibility for providing care for 
most patients with diabetes has fallen to primary care.  However in many areas, the 
infrastructure to deliver an effective care is inadequate due to a variety of factors, including the 
lack of coordination between primary and secondary care. The Erewash Diabetes Service 
(EDS) in Derbyshire provides a novel set up of diabetes care which integrates delivery of its 
services across both primary and secondary care derived from experiences from two Southern 
Derbyshire Integrated service models - First Diabetes and Intercare Health [5] -and built on a 
strong consensus among policy-makers and patient groups on the importance of improving 
integrated care in the NHS [6,7]. This service model brings primary and secondary care 
together in a clinical, financial, and legal not-for-profit company, using programme budgeting, 
shared electronic clinical records, and integrated clinical governance to deliver clinical care to 
patients throughout their clinical journey and has received local and national recognition [8-
10]. Clinical demographic data and clinical outcome among insulin treated patients with T2D 
within this model however is not available.  
 
We therefore aimed to identify individual information of insulin users with T2D, who received 
medical care in Erewash, with a view of characterising their demographic profile, insulin 
regimen, and cross sectional clinical outcomes parameters (as HbA1c, weight and lipid profile), 
compared with the UK national data, with a view of identifying local differences for audit and 
improved clinical practice in our area.  
Methods 
Study Population and Design: 
Based on the latest National Cardiovascular intelligence Network figures, the 2015 prevalence 
of diabetes in the Erewash region is 8.4%, which is higher than the national prevalence of 
6.55%. According to the 2015 Director of Public Health Annual Report for Derbyshire, 68.8% 
of adults in Derbyshire are classed as overweight or obese. This is higher than the East 
Midlands regional figures at 66.7% and the national figures for England at 64.7%. 
A comparative cross-sectional study was conducted among people with T2D on insulin 
therapy, using local data obtained of patient population from 6 randomly selected Primary Care 
practices in Erewash, Derbyshire CCGs. This was compared with a cross-section of the UK 
national UK Primary Care data via The Health Improvement Network (THIN) database, a UK 
computerised anonymised longitudinal Primary Care records with details of over 10.5 million 
patients of which 4.8 million are currently active. These were derived in a non-interventional 
manner from 532 General Practices within the UK and contains information on important 
variables as demography, lifestyle factors, disease diagnoses, hospital admissions, laboratory 
results, drug prescriptions, and socio-economic status. THIN has been validated to be 
demographically representative of the UK population and has been invaluable in evaluating 
clinical outcomes [11]. We selected only patients with Insulin treated T2D as this is the most 
challenging group of patients with T2D, many of which require specialist multidisciplinary 
input and would best highlight the clinical effectiveness of a given model of a specialised 
diabetes service.  
Six Primary Care centres were randomly from the 12 centres in the Erewash CCGs. Data from 
the centres were extracted via PRIMIS audit tool [12]. In both this and the THIN dataset 
population groups, we obtained data on all adult T2D insulin users, aged 18 and above, who 
initiated insulin therapy between January 2007 and 2014 in spite of previous or concurrent use 
of other glucose-lowering therapies (GLTs). Where similar patient identifiers were discovered 
in both populations, such patients were excluded. 
Exposure and Outcome: 
The main exposure was the use of insulin while the outcome was to compare demographic and 
clinical parameters among insulin-users, between the local Erewash Integrated service data and 
the UK national (THIN data).  
Covariates: 
Baseline demographic parameters as age, sex; clinical measures as body weight, body mass 
index (BMI) and blood pressure (systolic and diastolic); biochemical parameters as baseline 
HbA1c, creatinine level, total cholesterol levels, low-density lipoprotein (LDL), high-density 
lipoprotein (HDL) and triglycerides; as well as diabetes profile as the duration of diabetes, 
duration of insulin use; insulin regimen and the duration of treatment of diabetes were extracted 
and compared between these population groups.  
Statistical Analyses: 
Descriptive statistical analysis was done to obtain the mean and frequency distribution of the 
baseline demographics in both population groups.  
Pearson’s Chi-squared tests and independent student t-test were used to summarise and 
compare the categorical and continuous baseline variables respectively between the population 
groups. In the THIN dataset, missing data were generally accounted for using multiple 
imputations with the chained equation (MICE) model.  
 
All analyses were conducted using Stata Software, version 14 with statistical significance put 
at a p-level ≤ 0.05. 
Results: 
Patients Characteristics: 
There were a total of 18,533 insulin-users of which 18,227 were derived from the UK national 
data, and 326 from the Erewash data. The mean age was 61.6±13.6 years, while a little above 
half of the population (53.2%) were males. The mean HbA1c level was 8.7±1.8%; weight: 
91.2±18.7kg; with a greater proportion (62.5%) obese. Also, in both populations, Metformin 
(84.9%) was the commonest glucose lowering therapy (GLT) in use, followed by 
sulphonylurea (74.6%); thiazolidinedione (31.1%) and DPP4i (Dipeptidyl peptidase-4 
inhibitor) (13.9%); while the least used GLT is Sodium-glucose Cotransporter-2 inhibitors 
(SGLT2) (0.5%). Finally, the premix insulin regimen was the commonest regimen in use. Table 
1 is a summary of the baseline characteristics of the study population. 
 
Insulin-users with T2DM: Erewash Integrated Diabetes service vs UK 
i. DemographicCharacteristics: 
An independent t-test and chi-square test was run on both population samples to determine 
differences in the demographics of insulin-users with T2DM in both population groups (Table 
2). The baseline age was 4.6years significantly lower in the UK general population (61.5years 
vs 65.8 years; p <0.0001). There were similarities in gender distribution between both 
population groups (Males: 53.2% vs 54.0%, X2 = 0.0818; p = 0.775).  
ii. Clinical Parameters: 
We explored the differences in important clinical parameters which predict treatment outcomes 
in the management of T2D.  It was observed that HbA1c was similar in both populations (8.7% 
vs 8.5%; mean diff: 0.46; [95%CI: -0.16, 0.25]; p =0.6551), but the duration of insulin use 
(6.3years vs 4.3years; mean diff; 2.61; [95%CI: 2.10, 3.10], p <0.0001) were significantly 
higher in the Erewash integrated service compared to the UK national data.  
 
Some clinical measures as weight (p = 0.0019); BMI (p < 0.0001); systolic BP (p=0.0015); 
diastolic BP (p< 0.0001); total cholesterol (p< 0.0001); low-density lipoprotein (p<0.0001) and 
the proportion of the obese sub-population group (51.2% vs 62.7%; p<0.0001) were 
significantly lower in the Erewash Integrated service population group, compared to the UK 
national data. Conversely, high-density lipoprotein (p<0.0001); and glomerular filtration rate 
(p=0.013) were significantly higher in the local population, while triglycerides (p=0.9859) was 
similar in both.  
 
iii. Use of Insulin and other GLTs: 
Although in both populations, there was a higher proportion of insulin users on basal-bolus 
than premix (UK: 59.0% vs 41.1% and Integrated service: 89.3% vs 10.7%; p <0.0001), the 
use of basal bolus was found to be very high (approximately 9:10) compared to premix in the 
Erewash local data (Table 2). 
Similarly, there were significant differences in the proportion of users of other GLTs between 
the two population groups, and in all GLTs of interest, we reported a lesser proportion of users 
in the local data of Erewash integrated service, compared to the national except in Sodium-
glucose Cotransporter-2 inhibitors (SGLT2i) in which 2.5% of the local integrated service 
population were taking, compared to 0.5% in the national data (p<0.0001). Also, the proportion 
of metformin users was highest in both populations (85.6% vs 50.0%) compared to other GLTs, 
followed by sulphonylureas (75.7% vs 14.4%); while glinides were the least used GLT in the 
local population (0.3%), against SGLT2i (0.5%) in the national data. 
 
iv. Achievement of NICE targets. 
  No significant difference was noted in the percentage of patients achieving NICE HbA1c target 
of 7.5% between the two population cohorts. However significantly higher number of patients 
within the Erewash cohort achieved NICE targets for total cholesterol, systolic and diastolic 
blood pressure, compared with the UK THIN population. Thus for the achievement of combined 
HbA1c, total cholesterol and blood pressure, 17.5% in the Erewash cohort achieved the 
combined target compared with 9.6% in the UL THIN cohort (p<0.0001). (Table 3) 
 
 
 
 
Discussion: 
This observational study reports the demographic, metabolic and cardiovascular risk 
parameters, use of insulin therapy/ regimens and choices of concurrent oral glucose lowering 
therapies among patients with T2D undergoing routine care at a local Integrated Diabetes 
service compared with a representative UK cohort. While simple conclusions cannot be made 
from this cross-sectional data analysis, some discussion and speculation can be derived.  
Firstly, the mean percentage of patients achieving the three NICE treatment targets of HBA1c 
<58mmol/mol, blood pressure of <140/80mmHg and total cholesterol <4mmol/L was 
significantly higher in the Erewash integrated service cohort compared with the UK (THIN) 
population. The mean HbA1c level and the % patients achieving HbA1c target of <7.5% within 
the Integrated care cohort was however comparable to the UK cohort. This was despite 
significantly longer duration of diabetes and of insulin therapy in the integrated care cohort. 
This is relevant because increased diabetes duration is known to be associated with progressive 
decline of HbA1c level [1], continual decline of C-peptide level [13,14] and reduced 
responsiveness to intensive insulin therapy [13], which is partly augmented by increased age. 
[15]. The latter is also relevant because our cohort is significantly older than the UK cohort. 
Importantly, cardiovascular risk profile such as systolic BP, diastolic BP, total cholesterol and 
low-density lipoprotein levels were significantly lower in the integrated care cohort compared 
to the UK population. The reason for this is not known but we would speculate that the 
implementation of cardiovascular risk reduction strategies among patients who receive their 
routine care in an integrated service is likely to be more robust than that in the general 
population. Unfortunately the extracted data did not provide us with information regarding the 
use antihypertensive statins and aspirin therapy in both patient cohorts. This study supports 
observation from a previous trial which randomised intermediate care clinics for diabetes 
versus usual care and reported greater achievement of achievement of all three of the NICE 
targets [16] in the intermediate care cohort. 
Secondly, we observed a significantly greater use of a basal bolus insulin regimen compared 
with the premixed insulin regimen, in the integrated service compared with the UK population. 
These two insulin regimen are the two most widely used insulin regimens but there remains no 
overall consensus regarding the most effective or optimal insulin regimen for patients with 
diabetes mellitus [17]. The basal bolus regimen, which consists of multiple daily injections of 
rapid-acting insulin pre-prandially, in addition to a long-acting basal insulin, most closely 
mimics the pattern of insulin secretion in individuals without diabetes [18]. The flexibility of 
this regimen is, however, undermined by its complexity in the need to count daily carbohydrate 
intake and adjust the insulin dose accordingly, as well as the lifestyle restrictions implicated by 
the high number of injections [19]. The premixed insulin regimen accounts for the majority of 
insulin prescriptions worldwide and consists of a fixed ratio of rapid-acting insulin and 
intermediate insulin combined; thereby eliminating the need for patients to mix the insulin 
themselves whilst also reducing the number of required daily injections. We would speculate 
that the much higher preference for a basal bolus insulin regimen relative to premixed regimen 
within an integrated service compared to the UK population reflects the greater patients’ access 
to clinicians and diabetes educators, required for the more complex basal bolus regimen, 
accorded by an integrated diabetes service. Similarly this may also influence the much lower 
use of concurrent oral glucose lowering therapy in the integrated cohort, except for the SGLT2 
inhibitor, a novel therapy for type 2 diabetes, associated with weight loss. The later may explain 
the lower mean weight in the integrated service population, compared to the UK population, 
despite the higher background prevalence of overweight and obesity in the Erewash region 
compared with the UK population. 
 
In a previous Cochrane systematic review on ‘Intervention to improve the management of 
diabetes mellitus in primary care and community settings’[20], 41 studies were included which 
involved more than 200 practices and 48,000 patients. Majority of these studies involved 
intervention study which focused on ‘up-skilling’ of primary care (non specialist clinicians) 
via postgraduate education, patient tracking systems or other systems for regular follow-up, 
provision of patient education and/or a link research nurse to liaise with patient and clinicians, 
the impact of nurses in replacing physicians and the effectiveness of a pharmaceutical care 
model in delivering advice on glucose lowering therapy. No studies were identified that dealt 
with trial or audit outcome of an integrated service as defined by the ‘Best practice for 
commissioning diabetes services’ [21] and the ‘a joint position statement from the Primary 
Care diabetes society, Association of British Clinical Diabetologist, Diabetes UK and the Royal 
college of Nursing [22].  Due to the cross sectional nature of this study, we were not able to 
investigate the health economic outcome, patient pathway and the patient experience of the 
integrated service – three of the most important non-clinical determinant of the success of an 
integrated service. Further prospective randomised trial is required to address the research gap.   
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Tables: 
Table 1: Baseline characteristics by population groups and differences between  
 
 
Population 
 
 
Baseline variable 
THIN 
cohort 
Erewash 
Integrated 
Service 
Total 
Differences* 
(95% CI) 
 
p-value 
 (N = 
18,227) 
(N = 326) (N = 18,533)   
      
Demographics      
Age (yrs), Mean (SD) 61.5 (13.6) 65.8 (12.7) 61.6 (13.6) -4.6 (-6.1, -3.1) <0.0001 
Gender, No. (%)      
Male 9695 (53.2) 176 (54.0) 9871 (53.2) 
X2 = 0.0818 0.775 
Female 8532 (46.8) 150 (46.0) 8682 (46.8) 
Clinical Parameters, Mean (SD)     
HbA1c (%) 8.7 (1.8) 8.5 (1.8) 8.7 (1.8) 0.4 (-0.16, 0.25) 0.6551 
             (mmol/mol) 72 (20) 69 (20) 72 (20) - - 
BMI (kg/m2) 32.5 (6.9) 30.3 (6.9) 32.5 (6.9) 1.63 (0.88, 2.39) <0.0001 
Weight (Kg) 91.3 (18.7) 86.1 (20.4) 91.2 (18.7) 4.54 (1.67, 7.42) 0.0019 
SBP (mmHg) 136.3 (23.0) 132.2 (14.2) 136.3 (23.0) 3.30 (0.64, 5.96) 0.015 
DBP (mmHg) 76.0 (10.8) 72.5 (9.2) 76.0 (10.8) 3.21 (2.02, 0.41) <0.0001 
TC (mmol/l) 4.5 (1.3) 4.1 (1.1) 4.5 (1.3) 0.34 (0.20, 0.49) <0.0001 
HDL (mmol/l) 1.2 (0.4) 1.3 (0.4) 1.2 (0.4) 
-0.03 (-0.08, -
0.02) 
<0.0001 
LDL (mmol/l) 2.4 (1.1) 2.1 (0.9) 2.4 (1.1) 0.36 (0.23, 0.48) <0.0001 
Triglyceride (mmol/L) 2.0 (1.2) 1.7 (0.8) 2.0 (1.2) 
-0.001 (-0.14, 
0.13) 
0.9859 
eGFR (mls/min/1.73m2) 62.3 (21.0) 63.8 (21.5) 63.1 (21.3) 
-1.35 (-3.73, -
1.04) 
0.013 
Diabetes duration (yrs) 3.9 (6.4) 8.7 (8.0) 6.3 (6.2) 
-3.08 (-3.81, -
2.35) 
<0.0001 
Duration of insulin use 
(yrs) 
4.3 (4.9) 6.3 (5.1) 4.3 (4.9) -2.61 (-3.1, -2.1) <0.0001 
      
BMI Categories, No. (%)      
≤ 24.9kg/m2 2455 (13.5) 56 (13.4) 2511 (13.5)   
25-29.9kg/m2 4343 (23.8) 103 (31.6) 4446 (24.0) X2 = 18.07 <0.0001 
≥ 30kg/m2 
11429 
(62.7) 
167 (51.2) 11596 (62.5)   
Other GLTs, No. (%)      
      Metformin 
15593 
(85.6) 
163 (50.0) 15756 (84.9) X2 = 316.13 <0.0001 
      Sulphonylurea 
13794 
(75.7) 
47 (14.4) 13841 (74.6) X2 = 634.39 <0.0001 
      Thiazolidinedione 5754 (31.6) 9 (2.8) 5763 (31.1) X2 = 124.12 <0.0001 
      GLP-1ar 1943 (10.7) 13 (4.0) 1956 (10.5) X2 = 15.12 <0.0001 
       SGLT2 85 (0.5) 8 (2.5) 31 (0.5) X2 = 25.37 <0.0001 
       Glinides 790 (4.3) 1 (0.3) 791 (4.3) X2 = 12.72 <0.0001 
       DPP4i 2569 (14.1) 11 (3.4) 2580 (13.9) X2 = 30.74 <0.0001 
Insulin Regimen      
      Basal-bolus 
10744 
(59.0) 
291 (89.3) 7518 (40.5) 
X2 = 122.15 <0.0001 
      Premix 7483 (41.1) 35 (10.7) 11035 (59.5) 
      
*Differences- This is a measure of the differences in the variables between the two populations (mean difference in continuous variables with 
95% confidence interval; and chi-square test in categorical variables).  
 
SD (standard deviation); Diabetes duration is time from first diagnosis of diabetes to date of initiating insulin; Duration of insulin is the time 
between initiation of insulin and date of commencing study 
 
MET (metformin); SU (sulphonylurea); GLP-1ar (Glucagon-like peptide 1); INS (insulin); SGLT2 (Sodium-glucose Cotransporter-2 
inhibitors); Glinides (Meglitinides); DPP4i (Dipeptidyl peptidase-4 inhibitors) 
 
BMI (body mass index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (haemoglobin A1c); HDL (high-density 
lipoprotein); LDL (low-density lipoprotein); TC (total cholesterol); eGFR (estimated glomerular filtration rate) 
Table 2: The proportion of patients achieving the NICE targets of HbA1c ≤7.5% (59 
mmol/mol); Blood Pressure <140/80 mmHg and Cholesterol: 4 mmol/l. 
 
 
THIN  
cohort 
Erewash 
Integrated 
Service 
 
 
Chi-square 
 
p-value 
HbA1c     
           < 7.5% 4,195 (27.0) 91 (28.0) 
0.1463 0.702 
           ≥ 7.5% 13,312 (73.0) 235 (72.0) 
     
Total Cholesterol     
           < 5.0mmol/L 12,025 (66.0) 258 (79.1) 
24.82 <0.0001 
           ≥ 5.0mmol/L 6,202 (34.0) 68 (20.9) 
     
Diastolic BP     
           ≤ 80mmHg 12,069 (66.2) 267 (81.9) 
35.37 <0.0001 
           > 80mmHg 6,158 (33.8) 59 (18.1) 
     
Systolic BP     
           ≤ 140mmHg 10,651 (58.4) 247 (78.8) 
36.69 <0.0001 
           > 140mmHg 7,576 (41.6) 79 (24.2) 
     
NICE Target* 1,750 (9.6) 57 (17.5) 22.64 <0.0001 
     
 
*NICE target: Proportion of patients achieving the NICE targets of HbA1c ≤7.5% (59 mmol/mol); 
Blood Pressure <140/80 mmHg and Total Cholesterol: 4 mmol/l. 
 
 
 
 
